...

Blog

Home  /  Careprost and Bimatoprost for Eyelashes: Evidence, Risks and Legal Status

Careprost and Bimatoprost for Eyelashes: Evidence, Risks and Legal Status

Illustration of an optometrist talking with a patient during an eye health consultation
18 Nov

Careprost is a name many people have come across while searching for longer or fuller eyelashes. Behind the brand name is a prescription eye medicine called bimatoprost, and that fact matters far more than the marketing around it. Anything that is applied near the eye and absorbed through the skin deserves the same care as any other medicine.

This guide explains what bimatoprost is, what clinical trials have actually shown, which side effects are known, how the legal position works in the UK and what to look out for when a product is sold outside regulated channels. It is educational information only, so please read the medical disclaimer near the end.

Key takeaways

  • Careprost is a brand name for a bimatoprost 0.03% eye solution, which is a prescription-only type of medicine.
  • Bimatoprost was first developed for raised pressure inside the eye. Longer lashes were noticed as a side effect, which led to a separate eyelash indication in some countries.
  • In the UK, the licensed use of bimatoprost eye drops is for glaucoma and raised eye pressure, not for cosmetic lash growth.
  • Possible effects include eye redness, itching, darkening of the eyelid skin and, with prostaglandin-type medicines, other changes around the eye that a doctor should assess.
  • Products from unregulated sellers can be counterfeit, mislabelled or contaminated, and eye products carry particular infection risks.

What is Careprost?

Careprost is a brand name used internationally for an eye solution containing bimatoprost at a strength of 0.03%. Bimatoprost belongs to a group of medicines called prostaglandin analogues, which are widely used to lower pressure inside the eye in people with glaucoma or ocular hypertension.

During early studies of bimatoprost for eye pressure, researchers noticed that people grew longer, thicker and darker lashes. That observation led to a dedicated trial, and a randomised eyelash growth trial compared bimatoprost 0.03% with an inactive vehicle solution over 16 weeks. In the United States, a bimatoprost product called Latisse was approved for eyelash hypotrichosis, meaning too few or too short lashes, in 2008.

Being approved in one country does not make a different brand sold elsewhere equivalent to it. Each product must have its own authorisation in the country where it is supplied, and the manufacturing, labelling and sterility of each version all matter. As far as we are aware, Careprost does not hold a UK marketing authorisation, and you can confirm the current position with a pharmacist or through the medicines regulator.

How does bimatoprost work on eyelashes?

Simple educational illustration of an eyelid margin showing where eyelash follicles sit
Eyelashes grow from follicles along the eyelid margin, close to the surface of the eye.

Eyelashes grow from small follicles along the edge of the eyelid. Like the hair on your scalp, each lash goes through repeating stages of growth, rest and shedding. The exact mechanism by which bimatoprost affects lashes is not fully settled, but it is thought to prolong the growth stage and increase the number of follicles in that stage at the same time.

The follicles sit very close to the surface of the eye. That closeness is why safety guidance for this type of medicine is so specific and why products must be sterile. Even a small amount of contamination near the eye can lead to an infection, which is one of the main reasons home-sourced products are a concern.

Understanding the eyelash growth cycle

Simple illustration of a three-stage cycle with small sprout icons representing the hair growth cycle
Hair, including eyelashes, grows in repeating cycles of growth, transition and rest.

Every lash follows a cycle. The growth stage is when the lash lengthens, the transition stage is a short period when growth stops, and the resting stage ends with the lash falling out and a new one starting. Lashes are short compared with scalp hair partly because their growth stage is brief.

Understanding this cycle helps explain a few practical points:

  • Normal shedding of a few lashes each day is expected and is not a sign of illness.
  • Replacement lashes take weeks to regrow, so changes cannot be judged quickly.
  • Any change that comes from prolonging the growth stage may fade after the medicine is stopped, as lashes return to their usual cycle.
  • Sudden or patchy loss is a different matter and is worth discussing with a GP, as it can have medical causes.

What do the clinical trials show?

The main published trial involved 278 adults with eyelash hypotrichosis. Participants were randomly assigned to bimatoprost 0.03% (137 people) or an inactive vehicle solution (141 people) for 16 weeks. The main measure was a clinician-rated scale of overall eyelash prominence, where an improvement of at least one grade counted as a response.

Chart 1: Participants with at least a 1-grade improvement in eyelash prominence at week 16

Bimatoprost 0.03% (n = 137)78.1%
Vehicle (inactive solution) (n = 141)18.4%

Source: randomised, vehicle-controlled trial published on PubMed (ID 21899919). Figures are shown as reported; results for individuals vary.

Even with the inactive solution, about one in five people showed some improvement, which is a reminder of how much natural variation there is in lash appearance. The difference between the two groups was statistically significant, and the trial also found greater increases in measured length, thickness and darkness in the bimatoprost group.

Some important limits apply. The trial used a regulated, sterile product under medical supervision, with eye examinations as part of the study. It does not tell us how any unlicensed or unregulated product performs, and it covered a fixed period rather than long-term use.

Known side effects and safety concerns

In the pivotal trial reported at the time of the eyelash approval, the most common adverse events were mild and local. The chart below shows the percentages reported.

Chart 2: Most commonly reported adverse events in the approval trial

Eye redness3.6%
Itchy eyes3.6%
Skin darkening (hyperpigmentation)2.9%

Bars are drawn on a 0 to 5% scale. Source: trade report of the approval trial (Ophthalmology Times). Rates in other settings, and with unregulated products, may differ.

Beyond these common effects, product information for prostaglandin analogues describes other points that a prescriber considers:

  • Eyelid skin darkening: this can happen where the medicine touches the skin and may or may not fade after stopping.
  • Iris colour change: prostaglandin eye medicines can increase brown pigment in the coloured part of the eye, and this change can be permanent.
  • Changes around the eye: some people notice a sunken look of the eyelid or deepening of the upper lid crease linked to loss of fat around the eye.
  • Eye pressure effects: bimatoprost lowers eye pressure, which matters for people already using glaucoma treatment.
  • Infection risk: contaminated solution or applicators can introduce bacteria to the eye area.
  • Uneven growth: the lashes on the two sides can differ in length, thickness or direction.

Anyone who notices eye pain, worsening redness, swelling, a change in vision or discharge should stop and seek medical advice promptly rather than waiting for it to settle.

Who needs to be especially careful?

Illustration of an optometrist talking with a patient during an eye health consultation
An eye health check helps a prescriber judge whether any prostaglandin medicine is suitable.

Some groups should not use a prostaglandin eye medicine without a prescriber’s advice, and in many cases should not use it for cosmetic purposes at all. A clinician would want to know about:

  • Existing eye conditions such as glaucoma, uveitis, macular swelling, dry eye or a history of eye infections
  • Any previous eye surgery or recent eye injury
  • Current eye drops or other prescribed medicines
  • Pregnancy, planning a pregnancy or breastfeeding
  • Use of contact lenses
  • Allergies to any ingredient, including preservatives
  • Being under 18, since safety in children has not been established for this purpose

An optician or ophthalmologist can examine the eye and advise on whether any of these points make a product unsuitable. This is one of the biggest advantages of a regulated route compared with ordering from a website with no health questions.

What is the legal position in the UK?

In the UK, bimatoprost eye drops such as Lumigan are authorised as prescription-only medicines for reducing raised pressure in the eye in conditions such as open-angle glaucoma and ocular hypertension. The licensed use is not cosmetic lash growth. Prescribers can sometimes use a medicine outside its licence, but that is a clinical decision made by a registered prescriber who takes responsibility for it, and it is a very different situation from buying a product online with no assessment.

The table below is a simplified summary. Licensing can change, so check the current position with a pharmacist or the regulator.

Product typeIntended purposeUsual UK positionWho decides on use
Bimatoprost eye drops (for example Lumigan)Raised eye pressure, glaucomaLicensed, prescription-onlyEye specialist or GP
Bimatoprost eyelash product (Latisse type)Eyelash hypotrichosisApproved in the US; not licensed for this use in the UKPrescriber, with any use outside licence at their own responsibility
Careprost and similar imported brandsMarketed for lash growthNot a UK-authorised product as far as we knowNo UK regulatory oversight of the product
Cosmetic lash serumsConditioning, appearanceSold as cosmetics under cosmetic rulesConsumer, with product safety checks

If you are curious about how prescriptions work in practice, our guide explains how to get a prescription through a GP, pharmacy or registered online service.

Why unregulated eye products are risky

Illustration of a magnifying glass over a checklist, representing checking a medicine source
Checking where a medicine comes from is a basic safety step.

The biggest concern with eye products is not only the active ingredient but everything else about the bottle. A sterile product made under controlled conditions is very different from one with unknown origins. Problems seen with unregulated medicines in general include:

  • Counterfeit or diluted products with the wrong strength or a different ingredient altogether
  • Contamination with bacteria or fungi because of poor manufacturing or storage
  • Missing, outdated or inaccurate safety information in the leaflet
  • No batch tracing if something goes wrong
  • No pharmacist or doctor checking whether the product suits your health history

Our article on unregulated imported products explains why the same warning signs apply across many different medicines sold online.

How to check a source before trusting it

If you are looking for any prescription medicine, a few simple checks help you separate regulated services from risky ones:

  1. Look the pharmacy up on the General Pharmaceutical Council register and check the details match.
  2. Be wary of any site that offers a prescription medicine without asking health questions or involving a prescriber.
  3. Check that a UK address and a named responsible pharmacist are shown.
  4. Be cautious about unusually low prices, claims of guaranteed results or pressure to buy quickly.
  5. Make sure the product comes with a patient information leaflet in English with a batch number.

These checks do not guarantee safety, but a source that fails them should be treated with great caution.

Lower-risk ways to care for lashes

Many people who want fuller lashes do not need a prescription medicine. Gentler options carry far fewer risks, although they also promise less dramatic change.

  • Remove eye make-up fully each night and avoid rubbing or pulling at the lash line.
  • Avoid very harsh eyelash curlers, waterproof formulas that need heavy rubbing to remove, and old mascara that may harbour bacteria.
  • Treat lash extensions, glues and tints with care, as allergic reactions and infections can occur; a patch test helps.
  • Consider cosmetic conditioning products that make no medicine claims, bearing in mind that evidence for them is limited.
  • Ask a GP about sudden thinning, which can be linked to thyroid problems, skin conditions, allergies or certain medicines.

Myths and facts

  • Myth: It is only a cosmetic serum, so it must be harmless. Fact: It contains a prescription medicine with a known side-effect profile.
  • Myth: All bimatoprost products are interchangeable. Fact: Strength, formulation, preservatives, sterility and licensing differ between products.
  • Myth: The results are permanent. Fact: Lashes tend to return to their previous state after the medicine is stopped.
  • Myth: If a website sells it, it must be legal. Fact: Sellers can operate outside UK rules, and a product being available online says nothing about its safety.

When to see a doctor or optician

  • Eye pain, marked redness, swelling or sensitivity to light
  • Blurred vision, halos around lights or any sudden change in sight (seek urgent care)
  • Discharge, crusting or an eyelid that becomes hot, swollen or very sore
  • A visible change in eye colour or a hollow look around the eye
  • Sudden or patchy lash or eyebrow loss
  • Any reaction after using a product bought from an unregulated source, in which case keep the packaging and tell the clinician what you used

Side effects from medicines can be reported through the Yellow Card scheme, which helps the regulator spot safety problems.

A note for readers outside the UK

Rules differ between countries. In the United States, a bimatoprost eyelash product has been approved for hypotrichosis and is available on prescription. Australia, Canada and New Zealand have their own regulators and licensing decisions, and imported products may not meet local standards. Wherever you live, the sensible steps are the same: speak to a doctor, optician or pharmacist, use a licensed pharmacy, and avoid products with unclear origins.

Frequently asked questions

What is Careprost?

It is a brand name for an eye solution containing bimatoprost 0.03%, a prescription-type medicine used in eye care and studied for eyelash growth.

Is Careprost licensed in the UK?

As far as we are aware, it holds no UK marketing authorisation. UK-licensed bimatoprost eye drops are authorised for glaucoma and raised eye pressure, not for cosmetic lash growth.

Does bimatoprost really make lashes grow?

A controlled trial found that a much larger share of people using bimatoprost showed improvement than those using an inactive solution, but individual results vary and the effect is not permanent.

Can it change eye colour?

Prostaglandin medicines used in the eye can increase brown pigment in the iris, and this change can be permanent. It is one reason medical supervision matters.

Is it safe to use during pregnancy?

Safety in pregnancy and breastfeeding is not established for cosmetic use, so a clinician should be consulted before using any prostaglandin product.

What should I do if I have already used an unregulated product?

If you have any eye symptoms, get medical advice promptly. Even without symptoms, mention it to an optician or doctor, keep the packaging, and do not continue using a product of unknown origin.

Conclusion

Bimatoprost is a real medicine with real evidence behind it, but that evidence comes from sterile, regulated products used under medical supervision. A brand name on a bottle sold online does not carry the same assurance. For most people who simply want better-looking lashes, gentle care is the lower-risk starting point, and anyone considering a prescription medicine should speak to a doctor, optician or pharmacist first.

Medical disclaimer

This article is for general educational purposes only and is not medical advice, diagnosis or treatment. Medicine licensing, availability and guidance change, and the comparison table is a simplified summary. Never start, stop or change a medicine without advice from a doctor, pharmacist or other qualified healthcare professional who knows your health history. In an emergency, call 999. For urgent advice in the UK, call NHS 111.

References

  1. Bimatoprost 0.03% versus vehicle for eyelash hypotrichosis: randomised, vehicle-controlled trial. PubMed. https://pubmed.ncbi.nlm.nih.gov/21899919/
  2. Ophthalmology Times. Bimatoprost gets nod as hypotrichosis treatment. https://ophthalmologytimes.com/view/bimatoprost-gets-nod-hypotrichosis-treatment
  3. Electronic Medicines Compendium. Lumigan 0.3 mg/mL eye drops, summary of product characteristics. https://www.medicines.org.uk/emc/product/2947/smpc
  4. NHS. Glaucoma. https://www.nhs.uk/conditions/glaucoma/
  5. Medicines and Healthcare products Regulatory Agency (MHRA). Yellow Card scheme. https://yellowcard.mhra.gov.uk/
  6. General Pharmaceutical Council. Register of pharmacies. https://www.pharmacyregulation.org/registers

SHOPPING CART

Sorry, nothing in cart.

SUBTOTAL:

$0.00
View Cart